- Home
- GHRS vs MDXG Comparison
GHRS vs MDXG Comparison
Compare GHRS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | MDXG |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 530.2M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GHRS | MDXG |
|---|---|---|
| Price | $24.21 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $41.38 | $9.00 |
| AVG Volume (30 Days) | 190.3K | ★ 1.5M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $10.96 | $3.03 |
| 52 Week High | $24.66 | $7.99 |
Technical Indicators
Market Signals| Indicator | GHRS | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 51.81 |
| Support Level | $12.65 | $3.45 |
| Resistance Level | $24.66 | $3.80 |
| Average True Range (ATR) | 1.55 | 0.12 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 92.71 | 65.71 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.